NEW YORK, October 20, 2017 /PRNewswire/ --
If you want a Stock Review on PFE, SNY, HRTX, or AERI then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Thursday, the NASDAQ
Composite ended the day at 6,605.07, down 0.29%; the Dow Jones Industrial Average edged 0.02% higher, to finish at 23,163.04; and
the S&P 500 closed at 2,562.10, marginally gaining 0.03%. US markets saw five out of nine sectors finishing the day
in red, three in green, and one in neutral territory. DailyStockTracker.com has initiated research reports on the following
Drug Manufacturers - Major stocks: Pfizer Inc. (NYSE: PFE), Sanofi (NYSE: SNY), Heron Therapeutics Inc. (NASDAQ: HRTX), and Aerie
Pharmaceuticals Inc. (NASDAQ: AERI). Daily Stock Tracker published comprehensive and free research reports on these stocks today
at:
http://dailystocktracker.com/register/
Pfizer
New York headquartered Pfizer Inc.'s stock finished Thursday's session 1.14% higher at
$36.24 with a total trading volume of 19.79 million shares, which was above its three months
average volume of 17.06 million shares. The stock has gained 11.17% in the previous twelve months and 11.58% since the start of
this year. The Company's shares are trading above their 50-day and 200-day moving averages by 4.26% and 7.77%, respectively.
Moreover, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative
Strength Index (RSI) of 60.97.
On September 20 th, 2017, research firm Morgan Stanley upgraded the Company's stock
rating from 'Equal-Weight' to 'Overweight'. PFE complete research report is just a click away and free at:
http://dailystocktracker.com/registration/?symbol=PFE
Sanofi
Shares in Paris, France headquartered Sanofi rose 0.99%, ending yesterday's session at
$50.02 with a total trading volume of 457,502 shares. The stock has gained 33.32% over the past
twelve months and 23.69% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by
1.91% and 7.60%, respectively. Moreover, shares of Sanofi, which researches, develops, manufactures, and markets therapeutic
solutions, have an RSI of 56.35. The complimentary report on SNY can be downloaded at:
http://dailystocktracker.com/registration/?symbol=SNY
Heron Therapeutics
On Thursday, San Diego, California headquartered Heron Therapeutics Inc.'s stock saw a drop
of 1.97%, to close the day at $14.95. A total volume of 646,918 shares was traded, which was higher
than their three months average volume of 616.23 thousand shares. The Company's shares have advanced 14.12% on a YTD basis. The
stock is trading above its 200-day moving average by 1.16%. Additionally, shares of Heron Therapeutics, which engages in
developing medicines to address unmet medical needs, have an RSI of 37.02.
On September 27 th, 2017, research firm Northland Capital initiated an 'Outperform'
rating on the Company's stock, with a target price of $40 per share. Sign up for your complimentary
research report on HRTX at:
http://dailystocktracker.com/registration/?symbol=HRTX
Aerie Pharmaceuticals
Shares in Irvine, California-based Aerie Pharmaceuticals Inc. ended the day 0.62% higher at
$64.85. A total volume of 443,332 shares was traded. The stock has gained 21.44% in the last one
month, 12.20% in the previous three months, 82.57% over the last twelve months, and 71.33% since the start of this year. The
Company's shares are trading above their 50-day and 200-day moving averages by 17.57% and 31.66%, respectively. Furthermore,
shares of Aerie Pharma, which focuses on the discovery, development, and commercialization of first-in-class therapies for the
treatment of glaucoma and other eye diseases, have an RSI of 67.81.
On October 16 th, 2017, research firm Needham reiterated its 'Buy' rating on the
Company's stock with an increase of the target price from $65 a share to $76 a share. Get free access to your research report on AERI at:
http://dailystocktracker.com/registration/?symbol=AERI
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent
departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please e-mail contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"),
provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary,
based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a
reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the
information herein. The Reviewer has only independently reviewed the information provided by the Author according to the
procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party
research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside
of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you ' re a company we are covering and wish to no longer feature on our coverage list contact us via e-mail and/or phone between
09:30 EDT to 16:00 EDT from Monday to Friday at:
E-mail: contact@dailystocktracker.com
Phone number: +27(207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com